The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice

Table 1

Patient demographics and disease characteristics.

		Mean	SD	Min–max
Age (years)	12,526	61.9	14.0	18.0–100.0
cDMARDs	11,511	61.8	13.9	18.0–99.0
bDMARDs	3,697	59.0	13.1	19.0–91.0
Disease duration (years)	9,069	11.1	10.6	0–77.4
cDMARDs	8,591	11.1	10.6	0–77.4
bDMARDs	2,387	13.7	10.5	0.3–61.1
DAS28-ESR	7,112	3.2	1.6	0–8.8
cDMARDs	6,728	3.2	1.6	0–8.8
bDMARDs	2,576	3.4	1.7	0–8.7
Tender joint count	8,842	3.6	5.6	0–28.0
cDMARDs	8,285	3.6	5.5	0–28.0
bDMARDs	3,057	4.4	6.3	0–28.0
Swollen joint count	8,842	3.6	5.5	0–28.0
cDMARDs	8,285	3.7	5.5	0–28.0
bDMARDs	3,057	4.2	6.1	0–28.0
Rheumatoid factor	4,115	137.4	297.5	0–5088.0
cDMARDs	3,846	139.4	300.0	0–5088.0
bDMARDs	1221	158.9	344.1	0–4886.0
ACPA	2282	110.5	198.3	0–2000.0
cDMARDs	2137	110.5	193.0	0–2000.0
bDMARDs	726	124.7	210.4	0–1816.0

SD = standard deviation; patients taking at least one cDMARD; patients taking at least one bDMARD.